Krystal Biotech (NASDAQ:KRYS) Releases Quarterly Earnings Results

Krystal Biotech (NASDAQ:KRYS) released its earnings results on Monday. The company reported $2.05 EPS for the quarter, beating the consensus estimate of $1.79 by $0.26, FiscalAI reports. Krystal Biotech had a return on equity of 19.34% and a net margin of 54.82%. The firm had revenue of $127.34 million for the quarter, compared to analysts’ expectations of $125.77 million.

Krystal Biotech Price Performance

KRYS opened at $332.29 on Monday. The stock has a market capitalization of $9.84 billion, a price-to-earnings ratio of 41.64 and a beta of 0.50. Krystal Biotech has a twelve month low of $184.02 and a twelve month high of $382.54. The company has a 50-day simple moving average of $337.46 and a 200 day simple moving average of $308.68.

Analyst Upgrades and Downgrades

Several research firms have issued reports on KRYS. Weiss Ratings upgraded Krystal Biotech from a “buy (b-)” rating to a “buy (b)” rating in a research note on Friday, October 23rd. Royal Bank Of Canada began coverage on shares of Krystal Biotech in a research note on Friday, August 14th. They set an “outperform” rating and a $400.00 target price for the company. Jefferies Financial Group reaffirmed a “buy” rating and set a $474.00 target price on shares of Krystal Biotech in a report on Monday, July 13th. Chardan Capital upgraded shares of Krystal Biotech to a “strong-buy” rating in a research report on Monday, August 3rd. Finally, Bank of America boosted their price objective on Krystal Biotech from $392.00 to $400.00 and gave the stock a “buy” rating in a report on Monday, September 21st. Two investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Krystal Biotech currently has a consensus rating of “Moderate Buy” and an average price target of $377.20.

Insider Activity

In other news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $359.32, for a total transaction of $8,983,000.00. Following the completion of the sale, the insider owned 1,302,145 shares of the company’s stock, valued at approximately $467,886,741.40. This represents a 1.88% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Dino A. Rossi sold 25,000 shares of the stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $329.12, for a total transaction of $8,228,000.00. Following the sale, the director owned 50,000 shares in the company, valued at $16,456,000. This represents a 33.33% decrease in their position. The disclosure for this sale is available in the SEC filing. 13.10% of the stock is owned by company insiders.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a biotechnology company focused on developing and commercializing genetic medicines for rare diseases. The company’s platform uses modified herpes simplex virus type 1 vectors to deliver functional genes to target tissues, with an emphasis on therapies that can be administered repeatedly.

Krystal’s lead product, VYJUVEK, is a topical gene therapy for wounds associated with dystrophic epidermolysis bullosa, a rare inherited skin disorder caused by mutations affecting type VII collagen.